Detalhe da pesquisa
1.
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Lancet Oncol
; 18(3): 347-356, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28209296
2.
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Lancet Oncol
; 14(6): 516-24, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23578724
3.
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Cancer
; 119(4): 748-55, 2013 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23011911
4.
Where do we go from here? - Opportunities and barriers to the career development of trial managers: a survey of UK-based trial management professionals.
Trials
; 21(1): 384, 2020 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32375851
5.
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Radiother Oncol
; 104(2): 155-60, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22857859
6.
"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Int J Radiat Oncol Biol Phys
; 81(5): 1488-94, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20934265
7.
Schistosoma mansoni surface proteins
Mem. Inst. Oswaldo Cruz
; 84(supl.1): 179-187, 1989. tab
Artigo
em Inglês
| LILACS | ID: lil-623576